⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688927 | 1.00 | — | — | |
| SCHEMBL3419839 | 1.00 | — | — | |
| SCHEMBL27661980 | 0.86 | ACE (0.33) | — | |
| SCHEMBL145545 | 0.85 | — | — | |
| SCHEMBL163401 | 0.85 | — | — | |
| SCHEMBL77336 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL113878 | 0.83 | ACE (0.46) | — | |
| Water SCHEMBL1598131 | 0.83 | ACE (0.46) | — | |
| Hydrochloric Acid SCHEMBL1721046 | 0.83 | ACE (0.46) | — | |
| SCHEMBL2737878 | 0.83 | ACE (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495502-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | claimed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259132-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| CN-101495502-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | disclosed |
| WO-2009032326-A1 | NEW TETRACYCLINE DERIVATIVES AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| EP-0974670-B1 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL CO (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001004091-A1 | NEUROTROPHIC 2-AZETIDINECARBOXYLIC ACID DERIVATIVES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-6143554-A | Process for producing optically active n-substituted azetidine-2 carboxylic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0974670-A2 | Process for producing optically active N-substituted azetidine-2-carboxylic acid compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-01-26 | — | — | EP | disclosed |